MIRA News and Press, MIRA Pharmaceuticals Inc.

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS Newswire / March 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Compa...

Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage ...

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / October 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a cl...

A look at the top 10 most actives in the United States Vivakor Inc. (VIVK) fell 1.7% to $0.29 on volume of 405,185,185 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 1.2% to $4.02 on volume of 383,901,873 shares AiRWA Inc. (YYAI) fell 10.7% to $0.12 on volume of 376,141,924 ...

A look at the top 10 most actives in the United States Vivakor Inc. (VIVK) rose 88.7% to $0.557 on volume of 185,876,920 shares Nuburu Inc. (BURU) rose 20.1% to $0.4041 on volume of 115,556,701 shares AiRWA Inc. (YYAI) rose 7.1% to $0.1439 on volume of 84,556,118 shares Adaptimmune Therap...

2025-10-16 09:30:04 ET DENVER, Colo., Oct 16, 2025 ( 247marketnews.com )- Wall Street opens today with biotech and AI stocks in sharp focus after a wave of clinical milestones, cutting-edge launches, and strategic shifts dominated headlines. Here’s what’s moving the market...

Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA / ACCESS Newswire / October 16, 2025 / MIRA Pharmaceuticals, Inc . (NASDAQ:MIRA) ("MIRA"...

Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinica...

Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily ...

MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical ...